Pfizer Inc. (PFE) And FDA Announce Protalix Biotherapeutics, Inc. (PLX) Approval Of Pediatric Indication For ELELYSO (taliglucerase alfa) For Injection, For Intravenous Use For The Treatment Of Type 1 Gaucher Disease
8/29/2014 11:00:08 AM
NEW YORK & CARMIEL, Israel--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by